September 19, 2013 — Building on their breast care analytics expertise, Volpara Solutions will launch VolparaAnalytics and VolparaDose at RSNA. VolparaAnalytics and VolparaDose (pending U.S. Food and Drug Administration (FDA) review) join VolparaDensity to round out a suite of breast care analytics designed to offer new insights from mammography volumetric data. Visit Volpara at RSNA in Hall A, Booth 5925.
VolparaDensity provides an objective, reproducible measurement of breast density designed to improve early detection among women with dense breasts.
VolparaAnalytics assists in quality assurance by monitoring critical elements of the mammography process, including metrics to help monitor mammography unit performance, metrics to help understand technologist performance and patient population data.
VolparaDose uses the volumetric breast information to better calculate patient-specific dose estimates using mammography vendor-neutral algorithms.
Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at sites across the globe helping radiologists assess breast density more objectively and helping them better consider who might benefit from additional screening. Highly correlated to breast magnetic resonance (MR) assessments, VolparaDensity generates an objective, automatic measurement of volumetric breast density and a FDA cleared BI-RADS breast density category. VolparaDensity supports most of the major digital mammography systems, can be displayed on digital mammography and picture archive and communication system (PACS) workstations and be integrated into mammography reporting systems.
For information: www.volparadensity.com
July 29, 2024 
